![](https://endpts.com/wp-content/uploads/2024/06/Martin-Babler-Alumis-CEO.jpg)
Martin Babler, Alumis CEO
Alumis files for IPO ahead of Phase 3 studies for second-gen TYK2 inhibitor
Precision immunology startup Alumis has filed to go public, pitching itself to Wall Street just three months after raising $259 million from private investors. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.